The orphan nuclear receptor NR0B2 could be a novel susceptibility locus associated with microsatellite‐stable, APC mutation‐negative early‐onset colorectal carcinomas with metabolic manifestation
- 22 October 2020
- journal article
- research article
- Published by Wiley in Genes, Chromosomes and Cancer
- Vol. 60 (2) , 61-72
Abstract
Colorectal cancer (CRC) is a high incidence cancer and major cause of cancer mortality. Though disease‐causing tumor suppressors for major syndromes are well characterized, about 10% of CRC is familial but without mutations in known tumor suppressors. We exhaustively screened 100 polyposis families for APC germline mutations and identified 13, which are APC mutation‐negative, microsatellite‐stable (MSS), and with undetectable mutation in known tumor suppressors. Whole exome sequencing in three probands uncovered two with germline frameshift NR0B2 mutations, c.293_301delTTGGGTTGGinsAC and c.227delT. Sanger Sequencing identified a third proband with NR0B2 c.157_166delCATCGCACCT frameshift mutation. All three mutations deleted the C‐terminus activation/repression domain of NR0B2, thus are loss‐of‐function mutations. Real‐time RT‐PCR performed on tumor and matched mucosa of one patient revealed that NR0B2 downstream targets, SMAD3 was derepressed while GLI1 was downregulated in the colonic mucosa compared to healthy controls. Truncated NR0B2 molecule was predicted to have weakened binding with interacting partners SMAD3, GLI1, BCL2, and RXRα, implying perturbation of TGF‐β, Hedgehog, anti‐apoptotic and nuclear hormone receptor signaling pathways. Immunostaining also revealed nuclear retention of the most severely truncated NR0B2 molecule compared to the wildtype. Microsatellite and sequencing analysis did not detect loss of wildtype allele in probands' tumors. The patient who acquired somatic KRAS mutation progressed rapidly whist the other two patients manifested with late‐onset obesity and diabetes. We propose that haploinsufficiency of NR0B2 is associated with a novel CRC syndrome with metabolic phenotypes.Keywords
Funding Information
- Biomedical Research Council (IAF 311019)
- National Medical Research Council (NMRC/00212012, OFIRG‐0004‐2016)
This publication has 54 references indexed in Scilit:
- Characterization of the Mitochondrial Localization of the Nuclear Receptor SHP and Regulation of Its Subcellular Distribution by Interaction with Bcl2 and HNF4αPLOS ONE, 2013
- Role of nuclear receptor SHP in metabolism and cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2011
- Arginine Methylation by PRMT5 at a Naturally Occurring Mutation Site Is Critical for Liver Metabolic Regulation by Small Heterodimer PartnerMolecular and Cellular Biology, 2011
- Systems-Level Analysis of Gene Expression Data Revealed NR0B2/SHP as Potential Tumor Suppressor in Human Liver CancerMolecules and Cells, 2010
- Promotion of colorectal cancer growth and metastasis by the LIM and SH3 domain protein 1Gut, 2010
- SHP (small heterodimer partner) suppresses the transcriptional activity and nuclear localization of Hedgehog signalling protein Gli1Biochemical Journal, 2010
- Mutations in the small heterodimer partner gene increase morbidity risk in Japanese type 2 diabetes patientsHuman Mutation, 2008
- A Susceptibility Gene Set for Early Onset Colorectal Cancer That Integrates Diverse Signaling Pathways: Implication for TumorigenesisClinical Cancer Research, 2007
- Hypotheses for the etiology of colorectal cancer — an overviewNutrition and Cancer, 1990
- Mutation and Cancer: Statistical Study of RetinoblastomaProceedings of the National Academy of Sciences, 1971